Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Why different trials on digitalis give conflicting data.

R Jaeschke1, G H Guyatt

  • 1Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Cardiovascular Drugs and Therapy
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abstracts of presentations to the Annual Meetings of the Canadian Society of Colon and Rectal Surgeons Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons: Canadian Surgery Forum, Toronto, Ont., September 6-9, 2007.

Canadian journal of surgery. Journal canadien de chirurgie·2023
Same author

Reconciling contrasting guideline recommendations on red and processed meat for health outcomes.

Journal of clinical epidemiology·2021
Same author

A systematic survey of randomised trials that stopped early for reasons of futility.

BMC medical research methodology·2020
Same author

Randomised trials with provision for early stopping for benefit (or harm): The impact on the estimated treatment effect.

Statistics in medicine·2019
Same author

Updated European Consensus Statement on diagnosis and treatment of adult ADHD.

European psychiatry : the journal of the Association of European Psychiatrists·2018
Same author

Low-intensity pulsed ultrasound for treatment of tibial fractures: an economic evaluation of the TRUST study.

The bone & joint journal·2017

Digoxin benefits a small subset of congestive heart failure patients, with trial result variations explained by chance, dosage, and disease severity. Further analysis clarifies these findings for heart failure therapies.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Digoxin is a medication used for heart failure.
  • Previous studies on digoxin in congestive heart failure (CHF) have shown variable results.
  • Understanding the factors influencing these outcomes is crucial for effective treatment.

Purpose of the Study:

  • To systematically examine outcomes from randomized, controlled trials of digoxin.
  • To reconcile discrepancies in reported clinical trial results for digoxin.
  • To identify factors contributing to variability in digoxin's efficacy in CHF patients.

Main Methods:

  • Systematic review of randomized, controlled trials involving digoxin.
  • Analysis of various outcome measures across different studies.

Related Experiment Videos

  • Evaluation of potential confounding factors such as chance, digoxin dosage, and heart failure severity.

    • Main Results:

    • Observed discrepancies in digoxin trial outcomes appear to be less significant than initially perceived.
    • Digoxin demonstrates efficacy, but clinically meaningful benefits are limited to a specific subgroup of CHF patients.
    • Factors like random chance, dosage, and patient disease severity contribute to the variability in study results.

    Conclusions:

    • The variability in digoxin trial outcomes can be explained by several factors, including chance, dosage, and patient characteristics.
    • Digoxin remains a viable treatment option for a select group of congestive heart failure patients.
    • Systematic examination of trial data is essential for clarifying treatment efficacy and guiding future research in heart failure therapies.